1.Association between sarcopenia and abnormal lipid metabolism in patients with liver cirrhosis and the potential benefits of transjugular intrahepatic portosystemic shunt
Qinnian LI ; Bilian ZHU ; Yingmei TANG ; Chenrui ZHANG
Journal of Clinical Hepatology 2025;41(4):768-772
With the progression of liver cirrhosis, patients often develop sarcopenia and lipid metabolism disorders, and the complex interaction between p sarcopenia and lipid metabolism disorders not only promotes the progression of liver cirrhosis, but also affects the prognosis and quality of life of patients. As an effective intervention for alleviating complications associated with liver cirrhosis, transjugular intrahepatic portosystemic shunt (TIPS) can improve sarcopenia to a certain degree by improving hepatic hemodynamics and reducing portal venous pressure. In addition, there might be varying degrees of changes in blood lipid levels after TIPS, which may be closely associated with the recovery of liver metabolic function and the alterations in hemodynamics. This article introduces the association between liver cirrhosis, sarcopenia, and lipid metabolism disorders, elaborates on the effect of TIPS on sarcopenia and abnormal lipid metabolism, and discusses related mechanism and clinical significance, in order to provide a theoretical basis for clinical treatment.
2.Application of ARIMA model in predicting the incidence of hepatitis E in Yunnan Province
Bilian ZHU ; Yingmei TANG ; Zhengrong DING ; Jibo HE ; Weimin BAO ; Qinnian LI
Journal of Public Health and Preventive Medicine 2025;36(4):37-41
Objective To explore the application of the Autoregressive Integrated Moving Average (ARIMA) model in predicting the number of reported hepatitis E cases in Yunnan Province,to use this model to predict the incidence trend of hepatitis E, and to provide reference for the scientific prevention and control of hepatitis E. Methods Monthly reported cases of hepatitis E in Yunnan Province from 2012 to 2021 were collected. The ARIMA model was established using SPSS 27.0, and the model was validated and parameters were optimized with data from January 2022 to December 2022. The optimal fitting model was used to predict the incidence of hepatitis E in 2023. Results Hepatitis E incidence in Yunnan Province showed a certain seasonal distribution, with most cases concentrated from March to August. All parameters of ARIMA(3,1,4)(1,1,1)12 passed statistical tests. The Ljung-Box test showed statistic Q =10.050, P = 0.346, residual sequence was a white noise sequence, and goodness-of-fit index stationary R² was 0.591. The model extrapolation effect was verified with 2022 data, and MAPE was 14.747, indicating that the model extrapolation effect was effective. The number of hepatitis E cases in Yunnan Province in 2023 was expected to be 1,086. Conclusion The ARIMA (3,1,4)(1,1,1)12 model shows good fitting performance for hepatitis E cases in Yunnan Province and can effectively predict short-term disease trends, providing a theoretical basis for formulating prevention and control measures for hepatitis E.